MBA RPh - Biocept VP Communications

BIOCDelisted Stock  USD 1.45  0.17  13.28%   

Insider

MBA RPh is VP Communications of Biocept
Phone858 320 8200
Webhttps://biocept.com

Biocept Management Efficiency

The company has return on total asset (ROA) of (0.5165) % which means that it has lost $0.5165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8694) %, meaning that it created substantial loss on money invested by shareholders. Biocept's management efficiency ratios could be used to measure how well Biocept manages its routine affairs as well as how well it operates its assets and liabilities.
Biocept currently holds 12.11 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Biocept has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biocept's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Qing LiangActinium Pharmaceuticals
N/A
Topher BrookeAytu BioScience
N/A
Robert LutzIbio Inc
55
Lisa MiddlebrookIbio Inc
N/A
Avinash MDActinium Pharmaceuticals
N/A
Christopher BrookeAytu BioScience
N/A
Nick DeLongIbio Inc
N/A
Melissa BerquistIbio Inc
N/A
Thomas IIIIbio Inc
57
Arun SwaminathanActinium Pharmaceuticals
N/A
Stephen KilmerIbio Inc
N/A
Randy MadduxIbio Inc
63
MBA MSActinium Pharmaceuticals
58
Dr MSActinium Pharmaceuticals
N/A
Dr DVMIbio Inc
54
Greg PyszczymukaAytu BioScience
44
Mike JenkinsIbio Inc
N/A
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. Biocept (BIOC) is traded on NASDAQ Exchange in USA and employs 50 people.

Management Performance

Biocept Leadership Team

Elected by the shareholders, the Biocept's board of directors comprises two types of representatives: Biocept inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biocept. The board's role is to monitor Biocept's management team and ensure that shareholders' interests are well served. Biocept's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biocept's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Terry, Senior Vice President - Commercial Operations
Pavel Tsinberg, Director Devel
Soon Hahn, Founder
MBA RPh, VP Communications
Samuel Riccitelli, CEO Pres
Michael MD, Chief VP
Antonio Paternostro, VP Sales
Philippe Marchand, Chief Officer
Antonino Morales, Interim Director
Darrell Esq, Chief VP

Biocept Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biocept a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Biocept Stock

If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges